Comparison in curative effects between tolvaptan and torasemide in treating acute attack of chronic heart failure

Zhang Li; Chen Wei

doi:10.3969/j.issn.1674-4055.2017.10.09

Abstract：Objective To compare the clinical efficacy between tolvaptan and torasemide in treatment of acute attack of chronic heart failure (CHF).Methods CHF patients (n=124, male 69 and female 55) were chosen from the Taihe Hospital of Hubei University of Medicine from Jan. 2014 to Mar. 2015. All patients were divided, according to random digital table, into tolvaptan group and torasemide group (eachn=62). The patients in 2 groups were given routine anti-CHF therapy, and tolvaptan group was orally given tolvaptan additionally and torasemide group, torasemide additionally. The levels of serum potassium, serum sodium and serum creatinine (SCr) were detected, left ventricular ejection fraction (LVEF) was measured with ultrasound examination, and 24-h urine volume was recorded every day in 2 groups at the time of hospitalization and after treatment for 7 d. The symptoms and signs (lung rale, edema of lower extremity and dyspnea) were reviewed.Results The symptoms of lung rale, edema of lower extremity and dyspnea were significantly relieved in 2 groups after treatment for 7 d, which was more significant in tolvaptan group (allP<0.05). The difference in levels of SCr, serum potassium and serum sodium had no statistical significance in 2 groups before and after treatment (allP>0.05). The level of LVEF increased in 2 groups after treatment, which was more significant in tolvaptan group (allP<0.05). The urine volume increased significantly in tolvaptan group compared with torasemide group after treatment for 4 d (allP<0.05).Conclusion Compared with torasemide, tolvaptan has more significant effects of relieving symptoms and signs and improving heart function, and has no influence on kidney function in patients with acute attack of CHF.